REGN
Regeneron Pharmaceuticals, Inc.
Balance sheet
| USDLine, in USD | Q3 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.3B | 8.6B | 9.0B | 10.8B | 7.7B | 5.7B | 3.6B | 3.2B | 2.8B | 1.4B | 1.0B | 1.0B | 900M | 694M | 308M | 527M | 249M | 341M | — | |
Inventory | 2.89B | 3.20B | 3.09B | 2.58B | 2.40B | 1.95B | 1.92B | 1.42B | 1.15B | 0.73B | 0.40B | 0.24B | 0.13B | 70M | 29M | 17M | — | — | — |
| Current assets | 20.8B | 18.0B | 18.7B | 19.5B | 15.9B | 14.0B | 9.8B | 7.7B | 6.4B | 4.3B | 3.2B | 2.9B | 2.1B | 1.8B | 1.2B | 666M | 358M | 426M | — |
Intangible assets | 1.32B | 1.26B | 1.15B | 1.04B | 0.92B | 6.7M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | 44.4B | 40.6B | 37.8B | 33.1B | 29.2B | 25.4B | 17.2B | 14.8B | 11.7B | 8.8B | 7.0B | 5.6B | 3.8B | 3.0B | 2.1B | 1.3B | 1.1B | 741M | — |
Current liabilities | 6.20B | 4.37B | 3.94B | 3.42B | 3.14B | 3.93B | 2.70B | 2.10B | 1.44B | 1.14B | 1.24B | 0.81B | 0.65B | 0.30B | 0.16B | 0.15B | 0.11B | 94M | — |
| 1.99B | 1.99B | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B | 0 | — | — | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 10.9B | 9.3B | 8.4B | 7.1B | 6.6B | 6.7B | 6.1B | 3.7B | 3.0B | 2.6B | 2.5B | 2.0B | 1.3B | 999M | 835M | 838M | 562M | 344M | — |
| Shareholders' equity | 33.5B | 31.3B | 29.4B | 26.0B | 22.7B | 18.8B | 11.0B | 11.1B | 8.8B | 6.1B | 4.4B | 3.7B | 2.6B | 2.0B | 1.2B | 486M | 528M | 397M | 422M |
| Shares outstanding | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 91.8M | 87.8M | — | — |
| Current ratio | 3.35 | 4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 | 3.59 | 3.18 | 6.01 | 7.37 | 4.49 | 3.28 | 4.55 | — |